Clinical Efficacy of Anlotinib as Second-line Treatment on Patients with Extensive Small Cell Lung Cancer
Objective To observe and analyze the clinical efficacy and adverse reaction of anlotinib as the second-line treatment on extensive small cell lung cancer. Methods We retrospectively analyzed the clinical data of the 30 patients with extensive small cell lung cancer. After the failure of the first-li...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2020-12-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2020.20.0369.htm |